EDIT
$12.53
Editas Medicine
($.42)
(3.24%)
EDIT
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.89)
Revenue:  $4.73 Mil
Wednesday
Nov 2
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EDIT reports earnings?
Beat
Meet
Miss

Where is EDIT's stock price going from here?
Up
Flat
Down
Stock chart of EDIT
Analysts
Summary of analysts' recommendations for EDIT
Score
Grade
Pivots
Resistance
$13.71
$13.33
$13.14

$12.76

Support
$12.57
$12.19
$12.00
Tweet
Growth
Description
Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.